Why am I not losing weight on Mounjaro?

Mounjaro (tirzepatide) is a once-weekly injection used in adults to support medical weight management and to treat type 2 diabetes. It works well for most patients who stay with it through the full titration, but "well" is not the same as "fast", and average results in trials are not the same as your individual curve. If the scales have stalled, or progress has felt slower than you expected, the cause is rarely a single thing.

Reasons a Mounjaro response may be slow or absent

The first thing to check is how long you have been on a therapeutic dose. Mounjaro starts at 2.5 mg weekly for four weeks — that starter dose exists to let the body adjust, not to produce meaningful weight loss. Most patients only begin to see steadier weight loss once they have been on 5 mg or higher for a few weeks. Judging the medicine on the first month, or on the starter dose alone, is the most common reason patients feel it "isn't working".

There are also patients for whom Mounjaro produces less weight loss than the trial averages suggest. In the SURMOUNT clinical programme, a sizeable group lost meaningful weight at every dose, but a smaller group lost less — sometimes much less — than the average. That non-responder pattern is recognised in the clinical literature and is part of why UK guidance frames pharmacological treatment as one tool within a broader weight-management approach rather than a guarantee.

Several common contributors stall response in patients who do generally respond well to the medicine:

• Still early in titration — under three to four months on a therapeutic dose.
• Inconsistent injection timing or missed doses.
• A drift in eating patterns once initial appetite suppression eases.
• Low protein intake, which makes the body more likely to lose lean tissue than fat.
• Poor sleep, chronic stress, and alcohol — all of which blunt weight-loss response.
• Other medications that promote weight gain.
• Underlying endocrine conditions such as hypothyroidism or PCOS.

For UK clinical framing of weight-management treatment, the NICE guidance is the standard reference, and the BNF entry for tirzepatide is what UK prescribers refer to.

The role of dose, timing and adherence

Dose is the simplest factor to look at first. If you have been on 2.5 mg or 5 mg for a while and weight loss has stalled, the next clinical conversation may be about stepping up to a higher dose, provided you have tolerated the current one well. Higher Mounjaro doses produce more average weight loss in the trial data, but the curve flattens at the upper end and not everyone needs to reach the licensed maximum of 15 mg. The right dose for you is the one that gives sustained progress towards your agreed clinical goals with tolerable side effects.

Timing and consistency matter more than patients sometimes realise. Mounjaro is a once-weekly injection, designed around its plasma half-life. The standard guidance is to inject on the same day each week, with up to four days' variation if needed. Frequent missed doses, long gaps, or restarting the titration after a long break all change the response curve. If you are not sure how to handle a missed dose, the SmPC and your prescriber are the right reference — guessing risks both under-dosing and a return of side effects.

Honest adherence questions help too: are you injecting correctly, into the recommended sites (abdomen, thigh or upper arm), and rotating sites week to week? A pen that is past its in-use expiry or that has been incorrectly stored can deliver less than a full dose. None of these are common, but they are worth a quick check before assuming the medicine has stopped working.

Diet, sleep and activity factors that matter

Mounjaro is not designed to be a standalone treatment. UK clinical guidance positions GLP-1 medicines as one part of a programme that also includes diet, activity and behavioural support. When weight loss stalls, the most useful place to look is usually the lifestyle layer — not because patients are doing anything "wrong", but because the body adapts and small drifts add up.

A few patterns we see in real reviews:

• Calorie intake has crept up. Once the strong appetite suppression of the first weeks eases, portions naturally rise. Tracking a normal day's intake honestly — including drinks — is often eye-opening.
• Protein is low. A diet that is low in protein during weight loss makes the body more likely to lose muscle, which slows metabolic rate and stalls the scales. Aiming for a palm-sized portion of protein at every meal is a useful default.
• Liquid calories have slipped back in. Sugary drinks, fruit juice, lattes and alcohol bypass much of the satiety signalling Mounjaro relies on.
• Sleep is consistently under six hours. Poor sleep blunts hunger-regulating hormones and increases cravings. It is one of the most underrated levers in weight management.
• Activity is mostly steady-state cardio. Adding two to three resistance-training sessions a week preserves muscle and improves the metabolic picture beyond what cardio alone does.
• Alcohol intake has not changed. A weekly drinks total of even modest amounts can offset a calorie deficit entirely.
• Stress is high. Chronic stress raises cortisol, which interferes with appetite signalling and visceral-fat patterns.

None of these are reasons to feel guilty — they are levers. Often a small change in two or three of them restarts weight loss without any change to the medicine. For a parallel framing on tolerability and the early weeks, see our piece on how long Mounjaro side effects last.

Plateaus — how to identify and what to do

A plateau is a stretch of three to four weeks or more during which the scales sit flat despite consistent treatment and broadly unchanged habits. They are extremely common, especially between month three and month six of treatment, and they are not the same as the medicine failing.

Some helpful framing on plateaus:

• Body composition can still be changing even when the scale number is not — losing fat and gaining or maintaining muscle is a desirable pattern that the scale alone hides.
• Fluid retention varies with sleep, salt, alcohol and the menstrual cycle, and can mask up to a few kilograms either way.
• The body adapts to any caloric deficit by reducing resting energy expenditure slightly. This is normal physiology, not failure.
• A plateau early in titration may simply mean you need more time at the current dose, or that a step-up is the next move.

What to actually do during a plateau depends on the context. The first step is honesty about the lifestyle layer — without judgement — and a check on adherence. If those are solid and you have been at the current dose for at least four weeks, your clinician may consider a dose step-up, provided you have tolerated the current one well. For more on that decision, see our piece on when to increase your Mounjaro dose for weight loss. If you have already reached an agreed weight goal, a plateau may be exactly what you want — the conversation then shifts towards maintenance.

Underlying conditions and other medications

Some medical conditions and medications blunt the response to GLP-1 treatment. Where weight loss is well below expectations despite good adherence and a sensible lifestyle pattern, a clinician may consider further investigation.

Conditions worth thinking about include:

• Hypothyroidism. Even subclinical thyroid dysfunction can blunt weight loss and is easily checked with a simple blood test.
• Polycystic ovary syndrome (PCOS). Insulin resistance and androgen patterns in PCOS can make weight loss harder.
• Cushing's syndrome. Rare, but considered where the clinical picture suggests it.
• Untreated obstructive sleep apnoea. Often missed, and a meaningful driver of treatment-resistant weight gain.
• Perimenopause and menopause. Hormonal changes shift body-fat distribution and metabolic rate; HRT may be part of the conversation in eligible patients.
• Depression. Both the condition and some of its treatments can affect weight.

Medications that promote weight gain include some antipsychotics, some antidepressants, corticosteroids used long-term, certain antiepileptics, beta-blockers in some patients, and insulin or sulfonylureas in patients with diabetes. None of these are a reason to stop the other treatment without clinical advice — your prescriber will weigh the trade-offs and may suggest alternatives where they exist.

When a clinician may consider switching treatment

If, after a reasonable period at a therapeutic dose with good adherence, side effects under control, and the lifestyle layer addressed honestly, response is still well below what would be expected, the conversation may shift to whether Mounjaro is the right medicine for you. That is a clinical decision, not a self-decision.

Options the clinician may discuss include:

• Continuing at the current dose for longer before changing course, particularly if there has been any progress.
• A step up to a higher Mounjaro dose if you are not yet at the maximum and have tolerated the current dose well.
• Adding more structured behavioural and dietetic support.
• Reviewing other medications for weight-gain risk.
• Switching to a different GLP-1 medicine — for example, Wegovy (semaglutide) — if there is a clinical reason a different mechanism may suit you better.
• Investigating an underlying condition that has not yet been ruled out.

Switching is not a defeat. Different patients respond differently to different GLP-1 medicines, and there is no shame in finding that the second option works better for you than the first. The point of treatment is sustained progress towards an agreed clinical goal — not loyalty to a particular medicine.

Working with your Farmeci clinician

In a Farmeci programme, every dose-change decision and every plateau review is a conversation. At each review, your clinician will look at your weight curve in context, your side-effect picture, your medications, your sleep and stress, and any new symptoms. Honest answers help most: vague descriptions of diet or activity make a useful review harder. The decisions about whether to wait, step up, add support, investigate further or switch are joint ones, made on the basis of what is actually happening for you. The MHRA safety updates and NICE guidance shape the framework; your clinician translates that into a plan that fits your life.